Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD PhD, Erica Kim, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142584

Published: 2020

Journal Articles

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample

Ghulam Rehman Mohyuddin, MD, Kellen Gil, Brian McClune, Nausheen Ahmed, Al-Ola Abdallah, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Saqib Abbasi

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-142978

Published: 2020

Journal Articles

A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma

Ghulam Rehman Mohyuddin, Jill Hampton, Muhammad Aziz, Sadik Khuder, PhD, Saad Ullah Malik, MD, Brian McClune, Al-Ola Abdallah, MD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-142045

Published: 2020

Journal Articles

Hospitalization at the End of Life in Myeloma Patients: Lessons from the National Inpatient Sample

Saqib Abbasi, MD, Brian McClune, Al-Ola Abdallah, MD, Leyla Shune, MD, Ghulam Rehman Mohyuddin

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142057

Published: 2020

Journal Articles

Maintenance and Consolidation Regimens after a Second Autologous Transplant for Multiple Myeloma: A Decade of Experiences

Ghulam Rehman Mohyuddin, MD, Maire Okoniewski, Osama Diab, MD, Siddhartha Ganguly, MD, Al-Ola Abdallah, MD, Leyla Shune, MD, Joseph P. McGuirk, DO, Brian McClune, DO

Blood (2019) 134 (Supplement_1): 5700.

https://doi.org/10.1182/blood-2019-130619

Published: 2019

Journal Articles

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Neil Dunavin, MD, Lih-Wen Mau, PhD MPH, Christa Lea Meyer, MS, Clint Divine, Al-Ola Abdallah, MD, Susan Leppke, MPH, Anita D'Souza, MBBS, Ellen Denzen, MS, Wael Saber, MD MS, Linda J. Burns, MD, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 832.

https://doi.org/10.1182/blood-2018-99-118423

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5760.

https://doi.org/10.1182/blood-2018-99-117654

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5642.

https://doi.org/10.1182/blood-2018-99-117497

Published: 2018

Journal Articles

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Erica Hochard, PhD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 5422.

https://doi.org/10.1182/blood.V130.Suppl_1.5422.5422

Published: 2017

Journal Articles

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 1856.

https://doi.org/10.1182/blood.V130.Suppl_1.1856.1856

Published: 2017

Journal Articles

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Varinder Kaur, MD, Al-Ola Abdallah, MD, Arjun Swami, MD, Shebli Atrash, Daisy V. Alapat, MD, Zhifu Xiang, MD, Pooja Motwani, MD, Fade Mahmoud, MD, Issam Makhoul, MD, Peter Dean Emanuel, MD

Blood (2015) 126 (23): 5019.

https://doi.org/10.1182/blood.V126.23.5019.5019

Published: 2015

Journal Articles

Characteristics and Prognosis Of IgM Multiple Myeloma

Shebli Atrash, MD, Qing Zhang, PhD, Xenofon Papanikolaou, MD, Christoph Heuck, MD, Aziz Bakhous, M.D., Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1881.

https://doi.org/10.1182/blood.V122.21.1881.1881

Published: 2013

Journal Articles

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Al-Ola Abdallah, MD, Shebli Atrash, MD, Jameel Muzaffar, MD, Nisar Ahmad, MD, Sajjad Haider, MD, Monica Grazziutti, MD, Senu Apewokin, MD, Zainab Shahid, MD, Alejandro Restrepo, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 2925.

https://doi.org/10.1182/blood.V120.21.2925.2925

Published: 2012

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Joshua Epstein, DSc, Adam Rosenthal, Christoph Heuck, MD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Nathan M Petty, Clyde Bailey, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 195.

https://doi.org/10.1182/blood.V120.21.195.195

Published: 2012

Journal Articles

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Sarah Waheed, MD, Monica Grazziutti, MD, Alejandro Restrepo, MD, Saad Z Usmani, MD FACP, Frits van Rhee, MD, PhD, Jameel Muzaffar, MD, Al-Ola Abdallah, MD, Bijay Nair, MD, Antje Hoering, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1962.

https://doi.org/10.1182/blood.V120.21.1962.1962

Published: 2012

Journal Articles

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Emily Hansen, MS, Doug Steward, Sarah Waheed, MD, Susan B. Panozzo, Nathan M Petty, Shebli Atrash, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 4083.

https://doi.org/10.1182/blood.V120.21.4083.4083

Published: 2012

Journal Articles

Conversion of Non-Secretory to Hyper-Secretory Myeloma: The Antithesis of the Common Pathway of Dedifferentiation with Myeloma Progression: A Case Study

Shebli Atrash, MD, Al-Ola Abdallah, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 5052.

https://doi.org/10.1182/blood.V120.21.5052.5052

Published: 2012

Journal Articles

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Bart Barlogie, MD, PhD, Alan Mitchell, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD FACP, Monica Grazziutti, MD, Alejandro Restrepo, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Senu Apewokin, MD, Shebli Atrash, MD, Aziz Bakhous, M.D., Sajjad Haider, MD, Surachit Kumar, MD, Jameel Muzaffar, MD, Zainab Shahid, MD, John Crowley, PhD

Blood (2012) 120 (21): 1850.

https://doi.org/10.1182/blood.V120.21.1850.1850

Published: 2012

NARROW

Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample

A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma

Hospitalization at the End of Life in Myeloma Patients: Lessons from the National Inpatient Sample

Maintenance and Consolidation Regimens after a Second Autologous Transplant for Multiple Myeloma: A Decade of Experiences

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Overall Outcomes of Bing-Neel Syndrome after Treatment - a Review of 40 Cases

Characteristics and Prognosis Of IgM Multiple Myeloma

Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma.

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Identifying the Outliers Among Gene Expression Profiling (GEP)-Defined Low-Risk Myeloma Patients Treated with Total Therapy 2 and 3 (TT2, TT3)

Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Conversion of Non-Secretory to Hyper-Secretory Myeloma: The Antithesis of the Common Pathway of Dedifferentiation with Myeloma Progression: A Case Study

Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (>300U/L) and Gene Expression Profiling (GEP)-70 Score >=+o.66

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only